INTRODUCTION {#s1}
============

Nasopharyngeal carcinoma (NPC) is highly endemic in southern China \[[@R1]\]. Radiotherapy is the primary treatment modality for NPC. Two-dimensional conventional radiotherapy (2D-CRT) has been effective in controlling NPC, but complications to organs at risk resulting from 2D-CRT are severe and lifelong. In the last decade, intensity-modulated radiotherapy (IMRT) has rapidly replaced 2D-CRT due to its technical and dosimetric superiority, and when resources permit, has become the most commonly used radiation technique for NPC.

The incidence of stage II NPC has greatly increased with improvements in diagnosis, and after treatment the 5-year overall survival is assumed to be 95% or higher \[[@R2], [@R3]\]. The high survival rate makes quality of life (QoL) increasingly important. Previous studies suggested that IMRT improved symptoms and QoL for NPC survivors \[[@R4]--[@R6]\]. However, all of these studies were confounded by the interference of chemotherapy \[[@R7], [@R8]\]. Moreover, while the previous studies treated NPC as a whole group and analyzed QoL, most patients had advanced loco-regional NPC. Only one randomized controlled trial compared QoL of IMRT versus 2D-CRT in early stage NPC \[[@R9]\]. This trial suggested that IMRT was superior with regard to speech problems and swallowing. However, another randomized controlled trial reported that there was no significant difference in patient-reported xerostomia between IMRT and 2D-CRT \[[@R10]\]. Moreover, in both studies the sample size was relatively small, and the follow-up time was only 1 year, and neither provided accurate information regarding the QoL of IMRT versus 2D-CRT in early stage NPC.

In developing regions, many patients are treated with 2D-CRT rather than IMRT because they have no access to IMRT or the financial burden of IMRT is too great. Although 2D-CRT provides a similar survival benefit for NPC as IMRT \[[@R11], [@R12]\], clinicians have begun to pay more attention to QoL. We conducted a cross-sectional study to compare the QoL between IMRT and 2D-CRT in patients with stage II NPC. The result of this study might help clinicians make treatment decisions and provide information to health workers on which health services are most beneficial.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

Of 106 stage II NPC patients, 47 received 2D-CRT and 59 received IMRT. Disease-free survival of all subjects was more than 3 years. Table [1](#T1){ref-type="table"} summarizes patients' characteristics.

###### Patient characteristics

                       2D-CRT (n=47)   IMRT (n=59)
  -------------------- --------------- -------------
  Gender                               
   Male                31(65.96%)      39(66.10%)
   Female              16(34.04%)      20(33.90%)
  Age (years)                          
   Median              44              42
   Range               25-68           22-64
  Follow-up (months)                   
   Median              64              50
   Range               44-89           38-61
  AJCC stage                           
   T1N1M0              11(23.40%)      10(16.95%)
   T2N0M0              15(31.91%)      9(15.25%)
   T2N1M0              21(44.69%)      40(67.80%)
  Chemotherapy                         
   Yes                 14(29.79%)      37(62.71%)
   No                  33(70.21%)      22(37.29%)

2D-CRT: two-dimensional conventional radiotherapy; IMRT: intensity-modulated radiotherapy.

QoL of IMRT versus 2D-CRT for the whole group {#s2_2}
---------------------------------------------

In the whole group, IMRT (n=59) had higher mean scores in head and neck related symptoms and broad aspects of QoL for patients with stage II NPC than 2D-CRT (n=47) (Table [2](#T2){ref-type="table"}). Clinical superiority of IMRT for QoL was significant on all functional scales and most symptom scales upon clinical interpretation (difference in mean scores≥10 points).

###### Mean quality of life scores of 2D-CRT versus IMRT for the whole group

  Scales                     2D-CRT (n=47)   IMRT (n=59)   t       p                
  -------------------------- --------------- ------------- ------- ------- -------- -------
  EORTC QLQ-C30                                                                     
   Global quality of life    65.07           16.08         81.21   15.59   −4.939   0.000
   Physical functioning      75.74           19.33         92.2    13.43   −4.792   0.000
   Role functioning          74.47           22.21         90.43   14.64   −4.112   0.000
   Emotional functioning     67.38           26.74         89.01   15.65   −4.786   0.000
   Cognitive functioning     60.99           29.34         87.59   13.22   −5.666   0.000
   Social functioning        61.35           24.35         91.13   13.39   −7.348   0.000
   Fatigue                   34.28           22.2          12.53   17.89   5.23     0.000
   Nausea/emesis             4.26            8.84          1.06    4.12    2.244    0.028
   Pain                      18.09           17.32         8.16    11.97   3.233    0.002
   Dyspnea                   11.35           15.97         4.96    16.99   1.877    0.064
   Insomnia                  38.3            25.99         19.15   24.81   3.654    0.000
   Appetite loss             15.6            18.19         1.42    9.72    4.714    0.000
   Constipation              7.09            18.31         3.55    17.35   0.964    0.338
   Diarrhea                  9.22            17.99         2.84    9.4     2.155    0.035
   Financial problems        44.68           27.17         21.28   24.5    4.386    0.000
  EORTC QLQ-H&N35                                                                   
   Pain                      11.52           12.35         3.37    5.4     4.147    0.000
   Swallowing                25.71           17.62         5.32    8.93    7.076    0.000
   Senses                    25.18           17.68         11.7    14.29   4.064    0.000
   Speech                    10.64           11.57         2.84    7.13    3.934    0.000
   Social contact            28.9            22.51         4.79    10.95   6.603    0.000
   Social eating             12.77           12.1          2.55    6.6     5.078    0.000
   Sexuality                 54.96           32.02         20.92   20.7    6.121    0.000
   Teeth                     44.68           29.71         13.48   19.24   6.044    0.000
   Opening mouth             29.08           23.69         7.09    13.79   5.499    0.000
   Dry mouth                 58.16           22.49         22.7    25.16   7.204    0.000
   Sticky saliva             9.93            18.28         4.26    16.47   1.581    0.117
   Coughing                  13.48           17.94         12.06   17.62   0.387    0.7
   Feeling ill               22.7            20.97         8.51    17.68   3.545    0.001
   Pain killers              2.84            9.4           2.84    9.4     0.000    1.000
   Nutritional supplements   23.4            18.28         12.06   16.19   3.186    0.002
   Feeding tube              0.000           0.000         0.000   0.000   0.000    1.000
   Weight loss               5.67            12.66         1.42    6.8     2.03     0.046
   Weight gain               2.13            8.24          7.8     14.27   −2.361   0.021

2D-CRT: two-dimensional conventional radiotherapy; IMRT: intensity-modulated radiotherapy; SD: standard deviation; EORTC QOL-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

QoL of IMRT versus 2D-CRT without concurrent chemotherapy {#s2_3}
---------------------------------------------------------

In the radiotherapy alone subgroup, IMRT (n=22) had better QoL outcomes than 2D-CRT (n=33), except on scales of nausea/emesis, diarrhea, sticky saliva, coughing, pain killers, feeding tube, weight loss, and weight gain. Differences of most scales between the two groups were significant (Table [3](#T3){ref-type="table"}).

###### Mean quality of life scores of 2D-CRT versus IMRT without concurrent chemotherapy

  Scales                     2D-CRT (n=33)   IMRT (n=22)   t       p                
  -------------------------- --------------- ------------- ------- ------- -------- -------
  EORTC QLQ-C30                                                                     
   Global quality of life    69.95           15.30         86.74   11.69   −4.364   0.000
   Physical functioning      80.61           19.10         97.58   8.11    −4.528   0.000
   Role functioning          80.81           20.46         98.48   4.90    −4.761   0.000
   Emotional functioning     74.49           23.75         95.08   14.47   −3.990   0.000
   Cognitive functioning     66.67           30.33         94.70   9.47    −4.959   0.000
   Social functioning        66.67           24.65         96.97   6.58    −6.712   0.000
   Fatigue                   26.94           19.84         6.06    8.21    5.391    0.000
   Nausea/emesis             4.04            9.35          1.52    4.90    1.306    0.197
   Pain                      13.64           17.90         5.30    7.95    2.350    0.023
   Dyspnea                   9.09            15.08         1.52    7.11    2.500    0.016
   Insomnia                  28.28           20.62         12.12   21.93   2.777    0.008
   Appetite loss             14.14           18.69         0.00    0.00    4.346    0.000
   Constipation              8.08            20.46         0.00    0.00    2.268    0.030
   Diarrhea                  7.07            18.18         1.52    7.11    1.584    0.120
   Financial problems        39.39           28.20         9.09    15.19   5.152    0.000
  EORTC QLQ-H&N35                                                                   
   Pain                      10.86           14.05         1.52    4.18    3.590    0.001
   Swallowing                22.22           18.00         1.89    5.10    6.129    0.000
   Senses                    23.74           17.69         6.06    8.21    4.990    0.000
   Speech                    9.43            11.82         1.52    3.90    3.564    0.001
   Social contact            24.24           22.57         .38     1.78    6.046    0.000
   Social eating             12.12           11.72         .30     1.42    5.730    0.000
   Sexuality                 47.47           30.08         11.36   20.82   5.260    0.000
   Teeth                     40.40           32.01         9.09    18.35   4.599    0.000
   Opening mouth             27.27           25.62         1.52    7.11    5.468    0.000
   Dry mouth                 54.55           23.30         16.67   19.92   6.249    0.000
   Sticky saliva             7.07            16.15         1.52    7.11    1.739    0.089
   Coughing                  10.10           17.65         10.61   18.93   −0.101   0.920
   Feeling ill               18.18           20.57         6.06    16.70   2.400    0.020
   Pain killers              3.03            9.73          0.00    0.00    1.789    0.083
   Nutritional supplements   21.21           20.10         6.06    13.16   3.378    0.001
   Feeding tube              0.00            0.00          0.00    0.00    0.000    1.000
   Weight loss               2.02            8.08          1.52    7.11    0.238    0.813
   Weight gain               1.01            5.80          0.00    0.00    0.814    0.419

2D-CRT: two-dimensional conventional radiotherapy; IMRT: intensity-modulated radiotherapy; SD: standard deviation; EORTC QOL-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

QoL of IMRT versus 2D-CRT with concurrent chemotherapy {#s2_4}
------------------------------------------------------

In the concurrent chemotherapy subgroup, IMRT (n=37) had better QoL outcomes than 2D-CRT (n=14), except for symptoms of nausea/emesis, dyspnea, constipation, sticky saliva, pain killers, and feeding tube. Differences of most scales between the two groups were significant (Table [4](#T4){ref-type="table"}).

###### Mean quality of life scores of 2D-CRT versus IMRT with concurrent chemotherapy

  Scales                     2D-CRT (n=14)   IMRT (n=37)   t       p                
  -------------------------- --------------- ------------- ------- ------- -------- -------
  EORTC QLQ-C30                                                                     
   Global quality of life    53.57           11.65         73.2    15.48   −4.294   0.000
   Physical functioning      64.29           14.93         86.31   13.96   −4.933   0.000
   Role functioning          59.52           19.3          83.33   15.21   −4.628   0.000
   Emotional functioning     50.6            26.65         79.95   18.37   −4.48    0.000
   Cognitive functioning     47.62           22.51         77.48   15.82   −5.334   0.000
   Social functioning        48.81           19.02         82.43   16.17   −6.313   0.000
   Fatigue                   51.59           17.76         20.12   19.92   5.178    0.000
   Nausea/emesis             4.76            7.81          1.35    6.06    1.474    0.157
   Pain                      28.57           10.19         10.36   13.24   4.643    0.000
   Dyspnea                   16.67           17.3          6.31    18.98   1.78     0.081
   Insomnia                  61.9            22.1          24.32   23.11   5.243    0.000
   Appetite loss             19.05           17.12         2.7     12.12   3.276    0.004
   Constipation              4.76            12.1          4.5     19.5    0.046    0.964
   Diarrhea                  14.29           17.12         2.7     9.22    2.403    0.029
   Financial problems        57.14           20.37         35.14   27.16   2.747    0.008
  EORTC QLQ-H&N35                                                                   
   Pain                      13.1            7.1           6.31    6.92    3.106    0.003
   Swallowing                33.93           14.05         11.26   10.25   6.349    0.000
   Senses                    28.57           17.82         13.06   15.28   3.09     0.003
   Speech                    13.49           10.83         3       7.7     3.319    0.004
   Social contact            39.88           18.83         11.94   13.26   5.096    0.000
   Social eating             14.29           13.3          3.78    7.46    2.794    0.013
   Sexuality                 72.62           30.39         32.43   21.14   5.35     0.000
   Teeth                     54.76           21.11         23.42   22.03   4.583    0.000
   Opening mouth             33.33           18.49         15.32   21.65   2.959    0.006
   Dry mouth                 66.67           18.49         28.83   25.05   5.135    0.000
   Sticky saliva             16.67           21.68         4.5     17.85   1.872    0.076
   Coughing                  21.43           16.57         9.91    15.45   2.33     0.024
   Feeling ill               33.33           18.49         9.01    16.94   4.464    0.000
   Pain killers              2.38            8.91          3.6     10.49   −0.386   0.701
   Nutritional supplements   28.57           12.1          16.22   16.89   2.898    0.007
   Feeding tube              0.000           0.000         0.000   0.000   0.000    1
   Weight loss               14.29           17.12         0.9     5.48    2.87     0.012
   Weight gain               4.76            12.1          14.41   16.74   −2.273   0.03

2D-CRT: two-dimensional conventional radiotherapy; IMRT: intensity-modulated radiotherapy; SD: standard deviation; EORTC QOL-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

DISCUSSION {#s3}
==========

This study suggests that IMRT has better outcomes in both functional and symptom scales of EORTC QLQ-C30 compared to 2D-CRT with or without concurrent chemotherapy. The result indicates that IMRT should be provided to NPC patients, irrespective of a concomitant substantial increase in expenditures if resources permit.

We observed that 2D-CRT adversely affected patients with regard to symptom scales, global QoL, and functional scales compared to IMRT for the whole group. Differences of most functional and symptom scales were significant upon clinical interpretation. The result was similar to previous studies \[[@R4]--[@R6]\]. However, patients included in the previous studies were mostly T3-4 or N2-3. Radiotherapy combined with chemotherapy is the primary treatment modality for advanced loco-regionally NPC. It was suggested that concurrent chemotherapy adversely affected QoL of NPC patients \[[@R7]\]. None of these studies could totally exclude the interference of chemotherapy on QoL. In order to exclude the interference of chemotherapy, we conducted a subgroup analysis to compare the QoL of IMRT versus 2D-CRT without concurrent chemotherapy. The result revealed that IMRT alone significantly improved the QoL compared to 2D-CRT alone. Moreover, our subgroup result also suggested that IMRT had better QoL than 2D-CRT with concurrent chemotherapy.

It has been suggested that IMRT has significantly lower radiation-induced toxicity than 2D-CRT \[[@R13]\], but the change in the patient-reported xerostomia scores or QoL may be not statistically different between the two groups \[[@R10]\]. Possibilities to explain this inconsistency are as follow: (1) QoL assessment may contain questions that are not specific to RT-induced toxicities. (2) The criteria used to differentiate between grade 1 and grade 2 of QoL is rather vague and subjective. (3) Physician and patient bias may exist in an unblinded randomization setting. (4) Previous studies used a small sample size and a relatively shorter follow-up time. However, this study shows that IMRT has better QoL with or without concurrent chemotherapy in a longer follow-up time. The result further confirms that lower radiation-induced toxicities of IMRT may produce better QoL compared to 2D-CRT \[[@R9]\].

IMRT increases the expenses for NPC treatment and eventually increases the financial difficulties of individuals in developing countries such as China. Some studies found that financial difficulties adversely affected QoL \[[@R14], [@R15]\]. Consequently, IMRT would adversely affect QoL. However, we found that patients receiving 2D-CRT suffered from greater financial difficulties than those receiving IMRT. The potential interpretation was that patients received 2D-CRT because of financial difficulties. Financial burden after treatment gave patients receiving 2D-CRT worse QoL, but the relationship between financial problems and QoL is still unclear. Further controlled studies should be performed to test the interference of financial difficulties on QoL.

The result of our study should be interpreted with caution. The EORTC QLQ-H&N35 may have some limitations in assessment of QoL of NPC patients. NPC has different biological characteristics and treatment than other head and neck cancers. Xerostomia, deafness, otitis media, and symptoms from organs at risk injury after radiotherapy are the main symptoms in NPC survivors. Although the EORTC QLQ-H&N35 is a specific questionnaire assessing the QoL of head and neck cancer, it does not deal with adverse radiation effects well enough.

Limitations of this study should be considered: (1) The small sample size (106 patients) may lead to statistical error. (2) This study assessed the QoL at only one time point. A more methodologically sound approach would employ a longitudinal design in which the same individuals are assessed repeatedly at various time points.

In conclusion, this study suggests that IMRT improves most general aspects of QoL for patients with stage II NPC compared to 2D-RCT. IMRT is a better treatment technique for stage II NPC.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We analyzed QoL data of patients with stage II NPC in the Cancer Hospital of Guangxi Medical University from June 2008 to June 2013. Inclusion criteria were (1) pathologically proven NPC, (2) stage II NPC per the 7th Edition of the UICC/AJCC staging system, (3) receiving radical radiotherapy or concurrent chemotherapy, and (4) disease-free survival \>3 years. Exclusion criteria were (1) age \>70 or \<18 years, (2) recurrent or metastatic NPC, (3) receiving induced or adjuvant chemotherapy, (4) a second malignancy, except for cured skin basal cell carcinoma or early stage cervical cancer, (5) severe cerebral, cardiac, hematologic, renal, hepatic, or mental disease, or (6) an incomplete self-reporting questionnaire.

From June 2008 to June 2013, 235 patients with stage II NPC received radical treatment at the Cancer Hospital of Guangxi Medical University. There were 129 total excluded patients; 8 were lost to follow-up, 4 received induced chemotherapy, 40 received adjuvant chemotherapy, 5 died, 9 were loco-regional failures, 7 were distant failures, 51 were non-compliant, and 5 did not complete the questionnaire. This study finally included 106 patients treated with IMRT (n = 59) or 2D-CRT (n = 47).

Radiotherapy {#s4_2}
------------

Patients received 2D-CRT in two phases. In the first phase, patients were irradiated by 6-megavolt bilateral and opposing photon beams. The dose for the faciocervical field and lower anterior cervical field was 36 Gy. In the second phase, the dose for primary tumor was boosted from 66 Gy to 70 Gy. The prescribed irradiation dose was 2 Gy per fraction with 5 daily fractions per week.

Patients received IMRT per the International Commission on Radiation Units and Measurements Report 62 guidelines. Gross tumor volume (GTVnx) and cervical lymph node tumor volume (GTVnd) were determined by CT/MRI. Clinical target volume (CTV) included the GTV with a 1-cm to 1.5-cm margin, the entire nasopharyngeal space, and the positive lymph node regions. The prescribed radiation dose was 66 Gy to 70.06 Gy in 30 to 31 fractions for GTV, and 54 Gy to 60 Gy in 30 fractions for CTV with 5 daily fractions per week.

Chemotherapy {#s4_3}
------------

Patients received concurrent chemotherapy on days 1, 22, and 43 during radiotherapy. The chemotherapy regimen was cisplatin 100 mg/m^2^/d by intravenous infusion. Chemotherapy was postponed or discontinued for patients who experienced serious toxicity and could not recover before the next schedule.

QoL measurement {#s4_4}
---------------

Patients' QoL data were obtained by two clinicians from our department, both of whom received a uniform training. A subset of the patients was instructed to answer the questions during the visit to our clinic. Most patients were assessed by telephone. QoL data of all patients was analyzed by a third investigator. Consent was obtained from all patients included in the study.

QoL assessment used the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-questions (EORTC QLQ-C30) and the Head and Neck 35-questions (EORTC QLQ-H&N35) \[[@R16]--[@R19]\]. The EORTC QLQ-C30 is a cancer-specific questionnaire containing a global QoL score, five functional scales, three symptom scales, and six single items. The QLQ-H&N35 is a site-specific questionnaire assessing QoL of head-and-neck cancer patients. The QLQ-H&N35 contains seven multiple-item and six single-item scales. The standard score of all scales ranges from 0 to 100. A high score for a global QoL or functional scale represents a high/healthy level of global QoL or functioning, whereas a high score for a symptom scale represents a symptom problem. QoL changes of ≥10 points were considered clinically relevant \[[@R20], [@R21]\].

Statistical analysis {#s4_5}
--------------------

Statistical analysis was performed using SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL). The T-test was used to compare the mean scores of QoL between two groups. All significance tests were two-sided and P value \<0.05 was considered statistically significant.

Ethics statement {#s4_6}
----------------
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NPC

:   nasopharyngeal carcinoma

2D-CRT

:   two-dimensional conventional radiotherapy

IMRT

:   intensity-modulated radiotherapy

QoL

:   quality of life

GTV

:   gross tumor volume

CTV

:   clinical target volume

EORTC QOL-C30

:   European Organization for Research and Treatment of Cancer; Quality of Life Questionnaire-Core 30

EORTC QOL-H&N35

:   The EOTRC Quality of Life Questionnaire-Head and Neck 35.
